Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 2/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22747513 | 0.84 | ELANE (0.32) | PDE7AELANEBRD4ALDH1A1ESR2 | |
| SCHEMBL10005836 | 0.81 | BRD4 (0.43) | BRD4 | |
| SCHEMBL4072916 | 0.81 | BRD4 (0.33) | PDE7ABRD4 | |
| SCHEMBL10129561 | 0.81 | BRD4 (0.37) | ELANEBRD4ALDH1A1ESR2 | |
| SCHEMBL15186924 | 0.78 | BRD4 (0.35) | BRD4ALDH1A1 | |
| SCHEMBL20900689 | 0.78 | KAT2B (0.33) | BRD4ALDH1A1 | |
| SCHEMBL15372300 | 0.68 | PARP1 (0.41) | — | |
| SCHEMBL147830 | 0.65 | BRD4 (0.51) | BRD4 | |
| SCHEMBL10234059 | 0.65 | BRD4 (0.43) | BRD4ALDH1A1 | |
| SCHEMBL4076792 | 0.65 | KMT2A (0.41) | ELANEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218027-A1 | NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2024-07-04 | — | — | US | disclosed |
| US-11834479-B2 | Nucleoside triphosphate transporter and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-12-05 | — | — | US | disclosed |
| US-11530408-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20210071240-A1 | SINGLE-STRANDED BREAK DETECTION IN DOUBLE-STRANDED DNA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-03-11 | — | — | US | disclosed |
| US-20190292591-A1 | SYSTEMS AND METHODS FOR DETERMINING GENETIC DATA | Genia Technologies, Inc. (US) | 2019-09-26 | — | — | US | disclosed |
| US-20180193270-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | PURETECH LYT, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9914924-B2 | Methods and compositions for treating neurological disease | UNIVERSITY OF MASSACHUSETTS (US) | 2018-03-13 | — | — | US | disclosed |
| US-20170369871-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | Synthorx, Inc. | 2017-12-28 | — | — | US | disclosed |
| US-20170283801-A1 | THERAPEUTIC COMPOSITIONS | BANK OF AMERICA, N.A. | 2017-10-05 | — | — | US | disclosed |
| US-9708615-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-7723509-B2 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to target tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; biodrugs | ALNYLAM PHARMACEUTICALS (US) | 2010-05-25 | — | — | US | disclosed |
| US-20100076056-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100069471-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20090286973-A1 | LIGAND-CONJUGATED MONOMERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-7595306-B2 | Method of treating neurodegenerative disease | NATIONAL INSTITUTE OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-09-29 | — | — | US | disclosed |
| US-7582744-B2 | containing 2'-O-methyl modified nucleoside; oligonucleotide having a nucleotide sequence consisting of from 12 to 23 nucleotides in length sufficiently complementary to a microRNA target sequence of about 12 to 23 nucleotides, conjugate with a cholesterol or steroid; for inhibiting gene expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20070275914-A1 | Therapeutic Compositions | BANK OF AMERICA, N.A. | 2007-11-29 | — | — | US | disclosed |
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070161591-A1 | Methods and compositions for treating neurological disease | UNIVERSITY OF MASSACHUSETTS (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161595-A1 | Method of treating neurodegenerative disease | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193270-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | EXOSC5, EXOSC9, EXOSC10 | PDE7A 3282/4885ELANE 209/4885BRD4 1458/4885 |
| US-20100069471-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | NSUN2, RNGTT, DCLRE1B | PDE7A 2351/4885ELANE 2074/4885BRD4 1649/4885 |
| US-20070161591-A1 | Methods and compositions for treating neurological disease | SMN1; SMN2, CLN6, INA | PDE7A 869/4885ELANE 718/4885BRD4 2842/4885 |
| US-20070161595-A1 | Method of treating neurodegenerative disease | SNCA, PARK7, NLN | PDE7A 1772/4885ELANE 2689/4885BRD4 2743/4885 |
| US-20240218027-A1 | NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOF | SLC35B2, SLC29A2, PNP | PDE7A 581/4885ELANE 3910/4885BRD4 4849/4885 |
| US-20070275914-A1 | Therapeutic Compositions | AGO2, EXOSC5, RNASE1 | PDE7A 3203/4885ELANE 2998/4885BRD4 1591/4885 |
| US-11530408-B2 | Therapeutic compositions | SNRPE, HNRNPH3, RNASE1 | PDE7A 1861/4885ELANE 289/4885BRD4 2399/4885 |
| US-20100076056-A1 | MODIFIED iRNA AGENTS | LDLR, RNASE1, SARNP | PDE7A 979/4885ELANE 1088/4885BRD4 2582/4885 |
| US-20170283801-A1 | THERAPEUTIC COMPOSITIONS | SNRPE, HNRNPH3, RNASE1 | PDE7A 1861/4885ELANE 289/4885BRD4 2399/4885 |
| US-20090286973-A1 | LIGAND-CONJUGATED MONOMERS | TNFSF11, BCDIN3D, CD40LG | PDE7A 4379/4885ELANE 1838/4885BRD4 2305/4885 |
| US-20070179100-A1 | Protected monomers | PCNA, POLN, PARP1 | PDE7A 4856/4885ELANE 1776/4885BRD4 2420/4885 |
| US-11834479-B2 | Nucleoside triphosphate transporter and uses thereof | SLC35B2, SLC29A2, PNP | PDE7A 581/4885ELANE 3910/4885BRD4 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.